Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on October 31st, 2022% 
(Myriams-Fotos, Pixabay. https://pixabay.com/photos/milk-splash-drops-food-liquid-4755234/)
31 Oct. 2022. A developer of synthetic biology treatments for inflammatory and neurological disorders linked to the gut is becoming a public company through a special acquisition merger. Intrinsic Medicine Inc. in Seattle is joining with Phoenix Biotech Acquisition Corp. in Oakland, California, a special purpose acquisition company or SPAC, . . . → Read More: Gut-Brain Meds Developer Going Public in Merger
By Alan, on October 27th, 2022% 
Research with lab animals shows an experimental cancer vaccine generates immune-system cells that infiltrate solid tumors and reduce the tumor’s protective environment. . . . → Read More: Dual-Action Vaccine Shown to Attack, Shrink Solid Tumors
By Alan, on October 25th, 2022% 
A new biotechnology company is creating cancer immunotherapies that it says harness more of the full power of T-cells in the immune system to attack tumors. . . . → Read More: Immunotherapy Start-Up Launches Collaboration, Raises $65M
By Alan, on October 24th, 2022% 
A California state research agency is funding preclinical development of a gel designed to regenerate stem cells in the skin to help heal venous skin ulcers. . . . → Read More: Grant Funds Regenerative Gel for Treating Skin Ulcers
By Alan, on October 13th, 2022% 
A developer of bioactive hydrogels as alternatives to animal models for drug discovery and clinical lab tests is raising $3 million in its first venture round. . . . → Read More: Hydrogel Biomaterials Company Raises $3M in Early Funds
By Alan, on October 7th, 2022% 
Tests with lab animals show synthetic viral RNA particles, encased in natural oils, can safely invoke an immune response to attack solid tumors. . . . → Read More: RNA Cancer Immunotherapy Shown Feasible in Preclinical Test
By Alan, on October 6th, 2022% 
A developer of infectious disease vaccines is gaining funds for new nasal sprays protecting against a range of coronaviruses and the sexually-transmitted disease gonorrhea. . . . → Read More: Nasal Spray Vaccines Get CEPI, NIH Funding
By Alan, on October 4th, 2022% 
A vaccine grown in genetically-altered algae, designed as a nasal-spray and edible drug, is shown to protect lab mice against parasite infections causing malaria. . . . → Read More: Algae-Grown Non-Needle Malaria Vaccine in Preclinical Test
By Alan, on September 28th, 2022% 
A pharma/tech industry group is starting a new company to use algorithms for finding gaps in preclinical data that can impair clinical trial progress. . . . → Read More: Company Formed to Boost Clinical Trial Success Odds
By Alan, on September 20th, 2022% 
A charitable foundation promoting research on human longevity unveiled a challenge competition to develop animal-free testing for personalized medicine. . . . → Read More: Challenge Seeks Animal-Free Testing for Precision Meds.
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|
Comments are closed 
You must be logged in to post a comment.